POR6: EVALUATION OF THE STRUCTURAL VALIDITY OF THE SF-12  by Reed, PJ & Moore, DD
Abstracts 219
ing considered on each criterion in the preference struc-
ture; 4) Normalize and average the preferences for each
drug agent; 5) Create a statistic that indicates consistency
in quantifying the preferences; 6) Determine the prefer-
ence of each criterion relative to every other criterion in
the preference structure (normalize, average, and check
consistency); 7) Determine summary preference “score”
for each drug agent; 8) Choose the drug agent having the
greatest summary preference.
RESULTS: The optimal drug identified by the AHP was
the same drug agent identified by the Formulary Steering
Committee for inclusion in the formulary. However, the
AHP achieved this result with a comparable reduction in
inconsistency, greater efficiency and the ability to per-
form a sensitivity analysis of the outcome. 
CONCLUSIONS: The analytical hierarchy process can
be used to successfully identify appropriate drug agents
for formulary placement in managed care settings. Use of
this method allows formulary members to quantify their
subjective preferences among competing drug agents.
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OBJECTIVE: The purpose of the present study was to val-
idate the structural model of the SF-12 with data from the
1990 National Survey of Functional Health Status (NHS). 
METHODS: We used Confirmatory Factor Analytic (CFA)
to evaluate the structure of the MOS SF-12. CFA is ideally
suited for examining self-report survey tools, in that the
proposed structural characteristics are statistically evalu-
ated by comparing the estimated population covariance
matrix, estimated from the proposed parameters, to the
sample covariance matrix. 
RESULTS: There was substantial support for the hypoth-
esized structure of the SF-12; however, it was not a statis-
tically adequate fit (r2  1672.27; fit indices were well
below 0.9 [CFI  0.85]). The model was significantly im-
proved by adding a covariance path between Physical
Health and Mental Health, adding an additional link be-
tween General Mental Health and Physical Health, and the
addition of two covariances among the item errors. This re-
vised structure represented a good fit to the data (r2 
338.26; fit indices were well above 0.9 [CFI  0.97]). This
suggests that there are some commonalties between self-re-
ported Physical and Mental Health. This was supported by
the strong correlation between Physical Health and Mental
Health (r  0.838; 70% shared variance).
CONCLUSION: While there was some support for the
hypothesized structure, there was substantial evidence to
support the dependencies between Physical and Mental
Health. These findings are very similar to our previous
work with the SF-36 that suggests that a substantial por-
tion of these two constructs, Physical and Mental Health,
reflect a common construct. The SF-12 appears to be rel-
atively free of correlated errors, unlike the SF-36, and
may have fewer problems with systematic measurement
error or idiosyncratic interpretation of item content.
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OBJECTIVE: In recent years, a number of primers, stan-
dards, and guidelines have appeared in the pursuit of pro-
moting “good practice” and improving the overall quality
of economic evaluations. However, none of these contain
the logical next step: a scoring system that evaluates and
summarizes the quality of the studies. This research inves-
tigates whether a scoring system can be developed for pub-
lished economic evaluations, and discusses how such a sys-
tem can assist in clearly identifying studies of a better
quality, which in turn would provide the evidence to allow
priorities to be set in a more explicit manner. We construct
a scoring system based on an adaptation of the BMJ
Working Party 35-point checklist, and illustrate its appli-
cation to a case study of schizophrenia. 
METHODS: A comprehensive literature search was con-
ducted for the period 1966–1997. The inclusion criteria
were: 1) the study considered both the costs, and cost or
health consequences of alternative health programs for
schizophrenia; 2) the study was published in English; 3)
the majority (i.e., 50%) of the patients sampled had a
diagnosis of schizophrenia or related psychoses. The
studies were scored according to the maximum total
which could be achieved for each study. Selected items
(e.g., perspective) were given more weighting according
to their importance as determined by a recent survey of
health economists. 
RESULTS: Thirty studies met the inclusion criteria (17
US, 7 UK, 6 elsewhere). The studies either considered al-
ternative methods of service delivery or the use of novel
antipsychotic drugs (e.g., clozapine or risperidone). The
quality scores ranged from 43–88%. 
CONCLUSIONS: It is shown that our scoring approach
may be one reasonable method of summarising method-
ological quality. Further research needs to be performed
on the development of economic quality scoring methods
and the link between the quality of economic information
to their effects on decision-making.
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